Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.

Rachel H BhakNikita Mody-PatelScott B BaverColin KunzweilerChristopher W YeeSanjana SundaresanNatalia SwartzMei Sheng DuhSangeeta KrishnanSujata P Sarda

Published in: Current medical research and opinion (2021)

Results suggest that among patients previously treated with eculizumab, clinical, hematological, and quality of life endpoints were better for patients who received the C3 complement inhibitor pegcetacoplan vs. patients who received ravulizumab, a C5 complement inhibitor.

Keyphrases

blood pressure
atrial fibrillation
obstructive sleep apnea
newly diagnosed
sleep quality
physical activity